SLC29A1 and acute myeloid leukemia: Also, when we divided the AML samples in three subgroups based on their in vitro ara-C sensitivity, resistant patients expressed three-fold lower hENT1 mRNA levels compared to sensitive patients (P=0.003; Figure 3).